 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a virtual event discussing the companys pipeline, including omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant, and GDA-201, an investigational, natural killer NK cell-based cancer immunotherap 